

## 1 **Supplementary Materials**

## 2 **Supplementary Materials and Methods**

## 3 **Mitochondrial Clustering**

4 All image processing steps were performed in MATLAB using an approach established  
5 previously(1). Several masks were created and combined in order to isolate cytoplasmic  
6 autofluorescence. An SHG mask was primarily created to remove contributions from collagen and  
7 stromal autofluorescence at the interface of the epidermis and dermis. Contrast-limited adaptive  
8 histogram equalization (CLAHE) was applied to SHG images and features were subsequently  
9 segmented using Otsu's global thresholding. The SHG mask was finalized by applying a median  
10 filter to remove noise and taking the complement of the image to mask features corresponding to  
11 the segmented signal. Features corresponding to highly autofluorescent biomolecules such as  
12 keratin and melanin were masked using similar methods. CLAHE was applied to TPEF images  
13 and an Otsu's global threshold was calculated. Pixels with intensity values 1.5X greater than the  
14 Otsu's global threshold were segmented and masked. This empirically determined threshold was  
15 applied to all optical sections and was determined based on the propensity to remove highly  
16 autofluorescent signatures without masking pixels from intermediate cell layers which would not  
17 contain fluorophores such as keratin and melanin. The removal of nuclear and interstitial regions  
18 was achieved by applying 3 serial bandpass filters to contrast-limited adaptive histogram equalized  
19 TPEF images. Remaining features were segmented using Otsu's global thresholding. A circular  
20 mask with a 500-pixel diameter was created to remove dim image corner artifacts. Masks were  
21 finalized with the removal of objects less than 8-pixels in size. The final mask was applied to raw  
22 TPEF images, which were then subjected to a digital object cloning (DOC) process. The DOC  
23 process randomly fills any void pixels from the masking process with signal that was identified as  
24 cytoplasm. No pixels are overwritten during this process and it is replicated 5 times. The average  
25 power spectral density (PSD) of the 5 DOC images was then computed and fitted with an equation  
26 of the form  $R(k) = Ak^{-\beta}$  for spatial frequencies ( $k$ ) less than  $0.118 \mu\text{m}^{-1}$  (features smaller than  $8.5$   
27  $\mu\text{m}$ ). The absolute value of the fitted exponent,  $\beta$ , represents the degree of mitochondrial clustering  
28 within the cytoplasm. Mitochondrial clustering was computed for optical sections ranging from  
29 the stratum corneum to the stratum basale. Depth-dependent metrics of mitochondrial clustering  
30 were computed for each stack of images.  $\beta$  variability represents the sample variance of  $\beta$  values  
31 as a function of depth and aims to capture depth-dependent changes in metabolism. Median  $\beta$   
32 represents the median  $\beta$  value as a function of depth and aims to capture the overall level of  
33 metabolic activity.

34 Mitochondrial clustering was calculated in the same manner for single-cell analysis. Due to the  
35 relatively low levels of contrast in the basal layer of the epidermis, single cells had to be manually  
36 segmented. One optical section per patient region of interest was segmented for single cells.  
37 Approximately 5 – 10 single cells were masked per image. A total of 182 cells from lesional and  
38 258 cells from non-lesional regions were included for analysis. All vitiligo patients included in the  
39 imaging studies were represented in the total cell populations. The heterogeneity level of the  
40 corresponding distributions was quantified using a previously established heterogeneity index(2),  
41 based on fitting a 2-Gaussian mixture model to each distribution. Briefly, the heterogeneity index,

42  $H$ , can be computed using the equation  $H = -\sum d_i p_i \ln p_i$ , where  $i$  denotes each subpopulation,  
43  $d$  denotes the absolute value of the difference between the median of a subpopulation and the  
44 median of the total population, and  $p$  denotes the Gaussian mixing proportion of the subpopulation.  
45 2-Gaussian mixture models were derived using SAS JMP Pro 14 statistical software.

## 46 **Processing and quality control of scRNA-seq data**

47 Sequencing libraries were prepared using the Chromium Single Cell 3/ v2 protocol (10x  
48 genomics). Sequencing was performed on Illumina HiSeq4000 platform (Illumina). FASTQ files  
49 were aligned utilizing 10x Genomics Cell Ranger 2.1.0. Each library was aligned to an indexed  
50 hg38 genome using Cell Ranger Count. Cell Ranger Aggr function was used to normalize the  
51 number of mapped reads per cells across the libraries. Patient B sample and nonlesional skin of  
52 Patient G sample did not have enough viable cells and was excluded from further analysis (table  
53 S1). Quality control parameters were used to filter cells with 200-4000 genes with a mitochondrial  
54 percentage under 18% for subsequent analysis.

## 55 **Integration and clustering analyses of scRNA-seq data**

56 Integration and clustering of cells was performed using the scMC R package, which is a R toolkit  
57 for integrating and comparing multiple scRNA-seq experiments across different conditions. And  
58 scMC learns a corrected matrix, which is a shared reduced dimensional embedding of cells that  
59 preserves the biological variation while removing the technical variation(3). The data of each  
60 lesional and nonlesional skin of each patient were treated as one condition. Therefore, the input of  
61 the scMC is a list with 11 elements, with each element being one condition. The parameters used  
62 for this data are shown as follows: *resolution = 1*; *quantile.cutoff = 0.5*; *similarity.cutoff = 0.65*.  
63 To identify cell clusters, principle component analysis (PCA) was first performed on the corrected  
64 matrix of scMC and the top 40 PCs with a resolution = 1 were used to obtaining 14 clusters for all  
65 the samples.

## 66 **Calculation of signature score of a gene set**

67 For gene scoring analysis, most gene sets were acquired from the MSigDB database  
68 (<https://www.gsea-msigdb.org/gsea/msigdb/>). Gene sets of metabolic pathways were from  
69 published literature (4). Specific genes in each gene set and their sources are listed in Table S3.  
70 The AddModuleScore function in Seurat R package was then used to calculate the signature score  
71 of each gene set in each cell. The two-sided Wilcoxon rank sum test was used to evaluate whether  
72 there are significant differences in the computed signature scores between two groups of cells.

## 73 **Cell-cell communication analyses**

74 Recently we developed a new computational tool CellChat to systematically infer and analyze  
75 intracellular communication from scRNA-seq data. CellChat infers the biologically significant  
76 cell-cell communication by assigning each interaction with a probability value (i.e., interaction  
77 score or weight) and performing a permutation test. CellChat models the probability of cell-cell  
78 communication by integrating gene expression with prior known knowledge of the interactions  
79 between signaling ligands, receptors and their cofactors including soluble agonists and antagonists,  
80 as well as co-stimulatory and co-inhibitory membrane-bound receptors. The intercellular

81 communication networks for the nonlesional and lesional skin were separately inferred and then  
82 jointly analyzed using CellChat (version 1.1.0). The average expression of signaling genes per cell  
83 cluster was computed using the truncated mean, where 10% of expression levels were trimmed  
84 from each end of data. Since CellChat infers intracellular communications based on cell clusters,  
85 the interactions associated with cell clusters with very few cells were potentially artifacts. We thus  
86 filtered out the inferred interactions associated with stressed keratinocyte population in nonlesional  
87 skin because of the extremely low percent of stressed keratinocytes compared to other  
88 keratinocytes in nonlesional skin (fig. 3d). Genes and relevant pathways used by CellChat are  
89 listed in Table S4.

90

### 91 **Pseudotime and trajectory analysis**

92 The PHATE dimensional reduction of keratinocytes from all samples was performed by taking the  
93 shared low dimensional space obtained by scMC as an input. The parameters used in PHATE on  
94 the data are as follows:  $n_pca = 30$ ,  $t = 3$ . When inferring pseudotemporal trajectory of  
95 keratinocytes, the PHATE space was used the reduced dimensional space in Monocle 3(5). A  
96 principal graph is learnt by `learn_graph` function with the parameters:  $minimal\_branch\_len = 5$ ,  
97  $rann.k = 18$  and  $Euclidean\_distance\_ratio = 2$ . Pseudotime values of cells were obtained once  
98 cells were ordered based on the learnt graph. In addition, we also inferred the possible transitions  
99 between different cell subpopulations using PAGA by using the PHATE space as a reduced  
100 dimensional space.

### 101 **RNA velocity analysis**

102 RNA velocity was calculated based on the spliced and unspliced counts as previously reported (6),  
103 and cells that were present in the pseudotemporal trajectory analysis were used for the analysis. We  
104 used the python implementation “scvelo” with PHATE space as an input.

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119


120

121

122


123

124  
125



126 **Fig. S1. Mitochondrial Clustering Distributions for Basal Keratinocytes.** Mitochondrial  
127 clustering values were calculated for individually segmented cells from basal optical sections of  
128 vitiligo patients. The distributions were acquired by analyzing 182 cells from lesional regions  
129 and 258 cells from non-lesional regions. Counts were normalized to the corresponding cell totals.

130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146

148  
149

**Fig S2. Quality control metrics of the scRNA-seq data.** A) Violin plots of number of expressed genes (nFeature\_RNA), number of detected counts (nCount\_RNA) and percentage of mitochondrial genes (percent.mt) across all patients. B) Overlay the quality control metrics to the UMAP plot of integrative space.

153

154

155

156

157

158

159

160

161

162

163

164


165

166

167

168

169



170

171 **Fig S3. The difference between DC and TC.** A) Heatmap of top 10 differentially expressed  
 172 genes between DC and TC. B) Barplot of enrichment scores (-log<sub>10</sub>(p-value)) of enriched  
 173 human cell types inferred by Enrichr (<https://maayanlab.cloud/Enrichr/>).

174

175

176

177

178

179

180

181

182

183

184

185

186

187


188

189

190



191

192




**Fig S4. Analysis results of scRNA-seq data of normal skin from previously published data sets (7).** A) UMAP plot of healthy skin data generated from mammoplasty skin discards with cell clusters labeled. B) Feature plots showing expression of the stressed keratinocytes markers in the UMAP plot.

193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214




215 **Fig S5. Analysis results of scRNA-seq data of all patients by Seurat.** A) UMAP plot of the  
 216 combined data of all patients with cell clusters labeled in both lesional (left) and nonlesional skin  
 217 (right). B) Feature plots showing expression of the stressed keratinocytes markers in the UMAP  
 218 plot.  
 219

220  
 221  
 222  
 223







224  
 225 **Fig S6. Pseudotime analysis results of scRNA-seq data of all patients.** A) Marker genes'  
 226 expression levels change across PAPG graph. B) PAPG graph of the PHATE space. C) RNA  
 227 velocity across PHATE space.

228  
 229  
 230  
 231  
 232  
 233  
 234




235  
236  
237  
238  
239  
240

**Fig S7. Analysis Results of Published Acute Vitiligo Data Set.** A) TSNE plot of recently published healthy and patient-matched acute vitiligo nonlesional and lesional skin according to disease phenotype (left) and previously identified cell clusters (right) B) Feature plots showing expression of the stressed keratinocytes markers in the TSNE plot. C) Violin plot of stress markers in the acute vitiligo data set.



243 **Fig S8. Integrated Analysis of Cells from Both Acute and Stable Vitiligo.** A) UMAP plot of  
244 the cells from all cells in healthy, lesional (acute), nonlesional (acute), nonlesional (stable) and  
245 lesional (stable). Cells are colored by identity (top) and original annotated cell types  
246 (bottom). B) Feature plots showing expression of KRT6A, KRT16, CXCL10 and PMEL in the  
247 UMAP space of all cells. C) Heatmap of similarity scores between published cell types  
248 and our cell types. The similarity scores are computed by Spearman correlation coefficients  
249 between ratios of the number of each cell type in each identity. D) Heatmap of scaled expression  
250 levels of selected markers between healthy, lesional (acute), nonlesional (acute), nonlesional  
251 (stable) and lesional (stable) of cellular cluster identities 6 (Krt-ECR in acute vitiligo), 12  
252 (stress1 in stable vitiligo) and 15 (stress 2 in stable vitiligo).

253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272



273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301

**Fig S9. Metabolic signature scores from integrated analysis of cells from both active and stable vitiligo data sets.** Violin plots of signature scores of OxPhos and Glycolysis across healthy, lesional and nonlesional keratinocytes from active vitiligo and nonlesional, lesional and stress keratinocytes from stable vitiligo.

302 **Table S1. Clinical Characteristics of Stable Vitiligo Patients for MPM Imaging and**  
 303 **RNAScope**

Patient ID	Age	Sex	Imaging Location	Disease Status	Previous Treatments	Punch Grafting Treatment Status
1	61	M	Bicep	Stable vitiligo Generalized	Oral steroids, NBUVB, topical steroids	Responsive
2	34	M	Hand	Stable vitiligo Acrofacial	Topical steroids and tacrolimus, topical & oral Janus kinase inhibitor, NBUVB, PUVA, excimer	N/A
3	73	F	Neck/Back	Stable vitiligo Generalized	NBUVB, excimer, topical steroid, topical tacrolimus	Nonresponsive
4	45	F	Hand	Stable vitiligo Acrofacial	NBUVB, topical tacrolimus, topical steroid	Responsive
5	74	M	Hand	Stable vitiligo Acrofacial	Oral steroids, PUVA, NBUVB, Excimer, topical steroid, topical tacrolimus	N/A
6	58	M	Leg	Stable vitiligo Generalized	Oral steroids, NBUVB, Excimer, topical steroid, topical tacrolimus	Responsive
7	36	M	Leg	Stable vitiligo Generalized	NBUVB, topical tacrolimus	Nonresponsive
8	50	F	Face	Stable vitiligo Acrofacial	Oral steroids, Excimer, NBUVB, topical steroid and topical tacrolimus	N/A
9	72	F	Hand	Stable vitiligo Acrofacial	Oral steroids, Excimer, PUVA, NBUVB, Top tacrolimus, oral dexta, top steroid, Excimer, PUVA, NBUVB, punch grafting, topical Janus kinase inhibitor	N/A
10*	39	F	Leg	Stable vitiligo Generalized		N/A
11*	20	F	Ankle	Stable vitiligo Acrofacial		N/A
12*	36	M	Lower extremity	Stable vitiligo Generalized	NBUVB, topical steroid & tacrolimus	Nonresponsive

304 NBUVB, narrow band ultraviolet B; PUVA, psoralen + ultraviolet A; N/A, not available  
 305 \*Denotes patients who underwent punch grafting procedure and samples were used for RNAScope

306  
307  
308

**Table S2. Clinical Characteristics of Stable Vitiligo Patients for scRNA-seq.** The number of cells after quality control are shown.

Patient ID	Age	Sex	Areas of Involvement	Disease Status	Nonlesional cell count	Nonlesional Skin Suction Blister Site	Lesional cell count	Lesional Skin Suction Blister Site
A	69	F	Face, hands	Acrofacial	604	Upper thigh	1109	Dorsal hands
B	56	F	Face, neck, back, leg	Generalized	*	Upper thigh	*	Lower extremity/trunk
C	38	M	Feet and legs	Generalized	1235	Upper thigh	798	Lower extremity
D	30	F	Back	Focal	2729	Upper thigh	2568	Trunk
E	28	M	Face, hands	Acrofacial	2613	Upper thigh	3886	Dorsal hand
F	37	F	Legs	Generalized	747	Upper thigh	340	Lower extremity
G	67	F	Trunk	Focal	*	Upper thigh	553	Trunk

309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330

\*Insufficient viable cells and not included in analysis

1. D. Pouli, M. Balu, C. A. Alonzo, Z. Liu, K. P. Quinn, F. Rius-Diaz, R. M. Harris, K. M. Kelly, B. J. Tromberg, I. Georgakoudi, Imaging mitochondrial dynamics in human skin reveals depth-dependent hypoxia and malignant potential for diagnosis. *Sci Transl Med* **8**, 367ra169 (2016).
2. A. T. Shah, K. E. Diggins, A. J. Walsh, J. M. Irish, M. C. Skala, In Vivo Autofluorescence Imaging of Tumor Heterogeneity in Response to Treatment. *Neoplasia* **17**, 862-870 (2015).
3. L. Zhang, Q. Nie, scMC learns biological variation through the alignment of multiple single-cell genomics datasets. *Genome Biol* **22**, 10 (2021).
4. R. T. Davis, K. Blake, D. Ma, M. B. I. Gabra, G. A. Hernandez, A. T. Phung, Y. Yang, D. Maurer, A. Lefebvre, H. Alshetaiwi, Z. Xiao, J. Liu, J. W. Locasale, M. A. Digman, E. Mjolsness, M. Kong, Z. Werb, D. A. Lawson, Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. *Nat Cell Biol* **22**, 310-320 (2020).
5. J. Y. Cao, M. Spielmann, X. J. Qiu, X. F. Huang, D. M. Ibrahim, A. J. Hill, F. Zhang, S. Mundlos, L. Christiansen, F. J. Steemers, C. Trapnell, J. Shendure, The single-cell transcriptional landscape of mammalian organogenesis. *Nature* **566**, 496-502 (2019).
6. V. Bergen, M. Lange, S. Peidli, F. A. Wolf, F. J. Theis, Generalizing RNA velocity to transient cell states through dynamical modeling. *Nature Biotechnology* **38**, (2020).

331 7. G. Reynolds, P. Vegh, J. Fletcher, E. F. M. Poyner, E. Stephenson, I. Goh, R. A. Botting, N. Huang, B. Olabi,  
332 A. Dubois, D. Dixon, K. Green, D. Maunder, J. Engelbert, M. Efremova, K. Polanski, L. Jardine, C. Jones,  
333 T. Ness, D. Horsfall, J. McGrath, C. Carey, D. M. Popescu, S. Webb, X. N. Wang, B. Sayer, J. E. Park, V.  
334 A. Negri, D. Belokhvostova, M. D. Lynch, D. McDonald, A. Filby, T. Hagai, K. B. Meyer, A. Husain, J.  
335 Coxhead, R. Vento-Tormo, S. Behjati, S. Lisgo, A. C. Villani, J. Bacardit, P. H. Jones, E. A. O'Toole, G. S.  
336 Ogg, N. Rajan, N. J. Reynolds, S. A. Teichmann, F. M. Watt, M. Haniffa, Developmental cell programs are  
337 co-opted in inflammatory skin disease. *Science* **371**, (2021).  
338